PPAR-α is a ligand-induced nuclear receptor highly expressed in the liver, closely associated with biooxidation and fatty acid β-oxidation, and currently is used to treat dyslipidemia for it exerts an anti-inflammatory effect [42]. Here, PPARA is linked to metabolic syndrome.